Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

It also said the alliance will see Moderna invest in R&D in the UK over the next 10 years, including running ... "It is vital we invest in fighting future variants of this disease, as well as ...

Chief Executive Officer of Moderna. "We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the next three years, and reducing costs ...

Moderna saw a sharp decline in its COVID market share (US retail) from 48% to 40% only in 2024 – and the company expects a further decline this year. “As we head into 2025, there are a handful ...

Moderna has said it will open a new R&D and ... The facility is the centrepiece of a 10-year agreement-in-principle between the biotech and the UK government – which has been rumoured to be ...

The go-to-market feat of Moderna—the COVID ... but spotlight a $500 million gap. “We’ve actually offered guidance that we expect monthly losses this year,” explains Mock, who adds that ...

Moderna, Inc. (NASDAQ:MRNA) fell the largest on Monday, slashing 16.8 percent to close at $35.15 each after projecting a steep decline in its 2025 revenues to between $1.5 billion to $2.5 billion ...

Management's plans for the next three years entail a total of 10 product launches and, in 2027, reducing the annual sum it invests in research and development by $1.1 billion. Today, Moderna's ...

We recently compiled a list of the 10 Firms Drop on Bearish Statements, Disappointing Earnings. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the ...